Progress in therapy across the spectrum of advanced prostate cancer

In men with hormone-sensitive prostate cancer, enzalutamide and apalutamide improve overall survival compared with androgen deprivation therapy alone. Also, radiotherapy of the primary tumour is beneficial in patients with low tumour burden. In the non-metastatic castration-resistant setting, a posi...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Urology 2020-02, Vol.17 (2), p.71-72
Main Authors: Schmid, Sabine, Omlin, Aurelius
Format: Article
Language:English
Subjects:
631/67/589/466
692/699/67/1059
Androgen suppression therapy
Androgens
Care and treatment
Diagnosis
Humans
Male
Medicine
Medicine & Public Health
Metastasis
Neoplasm Staging
Patient outcomes
Prevention
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Prostatic Neoplasms - radiotherapy
Radiation therapy
Risk factors
Urology
Year in Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In men with hormone-sensitive prostate cancer, enzalutamide and apalutamide improve overall survival compared with androgen deprivation therapy alone. Also, radiotherapy of the primary tumour is beneficial in patients with low tumour burden. In the non-metastatic castration-resistant setting, a positive trial for darolutamide was reported. In the metastatic castration-resistant setting, the role of cabazitaxel in treatment sequencing was clarified. Key advances The phase III trials ENZAMET, ARCHES and TITAN demonstrated a significant benefit for the addition of enzalutamide or apalutamide to androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer 2 – 4 . The STAMPEDE trial showed practice-changing results for the addition of prostate radiotherapy to standard-of-care systemic therapy in metastatic hormone-sensitive prostate cancer 5 . The ARAMIS trial demonstrated a significant benefit for the novel androgen receptor (AR) antagonist darolutamide in non-metastatic castration-resistant prostate cancer 8 . The CARD trial set a new standard of care for cabazitaxel as the third-line treatment for metastatic castration-resistant prostate cancer in patients who had progressed on docetaxel and AR-targeted therapy 10 .
ISSN:1759-4812
1759-4820
DOI:10.1038/s41585-019-0270-7